

## Commercialisation of research outcomes. The 30 year journey at The University of Queensland

### **Dr Judy Halliday**

### **Senior Director – Commercial Engagement**

UniQuest





# Process of managing the transfer of research outcomes to broad market application





# Process of managing the transfer of research outcomes to broad market application





Satisfaction of bringing benefits to society - IMPACT

- creating jobs or curing disease; solving a problem for industry or

society

Industry Engagement

- expanded career options + enhanced 'employability' for graduates and staff

- Assuring relevance of teaching and research programs.

**Economic Benefit** 


National economic, social and political imperatives

Relative autonomy - Another source of funding for further R&D effort



## The challenge








## Ingredients for Success








## The process





(license or Start-up)



### **COMMERCIALISATION FOR IMPACT**




- UniQuest is one of Australia's largest and most successful university commercialisation groups (Founded 1984)
- From an intellectual property portfolio of 1500+ patents it has created over 70 companies
- Since 2000 more than A\$450 million has been raised to take university technologies to market
- \$3B annual sales of products based on UQ research outcomes and licensed by UniQuest
- UniQuest is a global top 10% of university commercialisation companies
- Unique embedded model





## The complexity - skills and people










- Improved risk profile
- Improved valuation
- Offering for investors is more "substantial"
- "whole is more than the sum of the parts"
- Collaboration

#### **Uni**Quest


- Increased complexity and cost in transaction
- Distribution of value
- Managing expectations
- Differing legal and regulatory environments
- Collaboration












- Does it makes sense business and science?
- Gaps and complementarity
- Appropriate focus on business deliverables
- Market need identified and quantified







- Do the parties need to be co-located?
- Jurisdictional variations in tax, corp law etc
- Availability of funding all forms
- CAPEX vs OPEX








- The most important!
- Still more important...
- Collaboration not convenience
- In the individuals, institutions and local environment.



#### Industry Engagement – Drug Discovery & Development





## **Track Record**



#### GARDASIL

More than 100 million doses of the HPV vaccine, Gardasil and have been distributed worldwide.



#### **IMAGE CORRECTION FOR MRI**

75% of high field MRI scanners use UQ image correction technology.



#### LYMPHEDEMA DIAGNOSIS

Bioimpedance diagnosis of lymphedema, covering over 20 million lives.



#### **EXTREMITY MRI SCANNERS**

GE Optima MR430s 1.5T extremity scanner uses novel magnet design by Magnetica.



#### TRANSIENT BLOCKING UNIT®

High-speed circuit protection devices using MOSFET semiconductors sold by Bourns.



#### LASER MACHINING OF TITANIUM ALLOYS

Technology used by Ferra Engineering to manufacture F-35 JSF components.



#### **SLOPE STABILITY RADAR**

Safety monitoring of open pit mines in over 20 countries.



#### **BIOPLASTICS FOR PACKAGING**

Corn starch-based bioplastics used by Cadbury, Nestle, Marks & Spencer, Coles and others.






#### SUCCESS!



- Surge protection components and modules for communications applications
- *"first new approach to electronics circuit protection in over a decade"*
- Richard Harris (Student), ITEE
- Patented in 1996
- Spinout in 2001 (Uniseed investment)
- Moved to US in 2004 (US VC investors)
- Acquired in 2008 by **BOURNS**\*
- Now used in:
  - Cell phone base stations
  - Data communications interfaces



- Systematic approach to improving parenting skills developed over many years by professor Matt Sanders, University of Queensland
- "It started as a doctoral thesis more than 30 years ago. Now with more than 250 published papers, including more than 140 clinical trials, studies and evaluations behind it, Triple P has become one of the world's mosttrusted parenting interventions, cited in reports by the World Health Organization, the US Centers for Disease Control and Prevention, and the United Nations among them" <u>http://www.triplep.net/</u>
- Licensed as a system (brand, training and publications)
- Licenses across the world (available in 25 countries)
- Translated into 20 languages
- >30,000 Triple P practitioners world-wide
- Constantly evolving to meet market eg Lifestyle Triple P, Workplace Triple P





#### SUCCESS!



- Vaccine for protection against HPV /cervical cancer
- First sales in 2006
- Over 100 million doses delivered.
- Professor Ian Frazer and the late
   Dr Jian Zhou at the Diamantina Institute
- Licensed to





#### SUCCESS!

## <u>GroundPr@be</u>®

- Slope stability radar
- Spin-out from CRC for Sensor Signal and Information Processing
- Incorporated in 2001
- 2003: Capital raising
- 2007: Revenue of \$21M
- Buyout by Crescent Capital Partners (Private Equity firm) in 2010




- 20+ lives saved in first years of operation
- 500+ wall failures detected
- 150+ radars deployed in 20+ countries
- 150+ people employed worldwide

- "The Company's Dual Opioid® platform technology – a patented fixed-ratio combination of morphine and oxycodone – provides effective analgesia while decreasing the frequency and severity of clinically important opioid-related side effects"
- Professor Maree Smith
- Patented in 1996
- Spinout in 2002 (multiple investors)
- ASX IPO in May 2007 (QRX raised AUD \$50 million)
- NDA filed 2011, refile expected Nov 2013
- Product Launch expected in 2H CY 2014:













## **QUESTIONS ?**





#### **INNOVATION ENGINE - A LEADING UNIVERSITY**

- Established 1910
- AU \$1.64 billion total operating revenue
- Leading Australian university in research and research commercialisation
- 45,548 students
- 11,398 international student from 134 countries
- 12,268 graduate students
- 7453 staff
- 200,000+ Alumni in 160 countries




## **ONE UNIVERSITY – FOUR CAMPUSES**









YEARS AHEAD

The University

OF QUEENSLAND

THE UNIVERSITY

## **A COMPREHENSIVE UNIVERSITY**



### **Six Faculties**

- 1. Arts (Humanities)
- 2. Business, Economics & Law
- 3. Engineering, Architecture & Information Technology
- 4. Health Sciences
- 5. Science (including Vet Science & Agriculture)
- 6. Social and Behavioural Sciences

### **Eight Institutes**

- 1. Australian Institute for Bioengineering & Nanotechnology
- 2. Institute for Molecular Bioscience
- 3. Queensland Brain Institute
- 4. UQ Diamantina Institute in the Translational Research Institute
- 5. Queensland Alliance for Agriculture & Food Innovation
- 6. Sustainable Minerals Institute
- 7. Institute for Social Science Research
- 8. Global Change Institute




## Research at UQ

- \$530m funding for research, from government, industry and philanthropy
- The 2012 Excellence in Research for Australia (ERA) exercise confirmed UQ as one of the nation's top three universities
- Research at UQ is well above world standard in more specialised fields than at any other Australian university
- UQ's outstanding critical mass offers researchers significant interdisciplinary capability
- Focus on quality across a broad range of fields
- Encourage technology transfer and commercialisation
- Focus on interdisciplinary research that addresses
   major challenges



### The process





## **Track Record**





**QRx Pharma –** MoxDuo for the treatment of severe to acute pain December 2011, partnered with Actavis, world's 4<sup>th</sup> biggest generic drug company, to develop and market MoxDuo IR (morphine and oxycodone) in the US. New Drug Application (NDA) has 25 June 2012 approval target date.

## spinifex

**Spinifex Pharmaceuticals –** Treatment of post-herpetic neuralgia September 2011, commenced treatment of 1st patients in Phase 2 clinical trial of EMA401 in PHN, a condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not always relieve pain.



**Xenome –** Novel non-opiate therapeutic for moderate to severe pain December 2011, closed A\$8 million financing in to fund Xen2174 Phase 2 clinical trial to demonstrate improved postoperative pain relief for an extended period following a single intra-thecal administration immediately prior to surgery.

Protagonist Therapeutics **Protagonist Therapeutics** – disulphide rich peptide drug discovery January 2011, entered into a collaboration with Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) to discover novel peptides for potential development.





Non-invasive diagnostic and monitoring for lymphoedema Affects 30% of women who undergo breast cancer surgery Approx. 400,000 Australian sufferers

1988	Research commenced
1999	Patent filed by UniQuest
2000	<ul> <li>ImpediMed Ltd established</li> <li>First investment from Pharma Corporation</li> </ul>
2004	<ul> <li>Regulatory submission &amp; market launch</li> <li>FDA approval</li> </ul>
2006	<ul> <li>Initial venture capital investment</li> <li>Launch into US and European markets</li> </ul>
2007	<ul> <li>Australian Stock Exchange listing</li> <li>\$18 million capital raise</li> </ul>
2011	American Medical Assoc. issues reimbursement



code






## Vaxxas Pty Ltd – Australia's second largest

#### first round investment in a university start-up

🕸 v a x x <u>a s</u>







#### The Technology

- Nanoprojections on a silicon 'patch' – low cost of manufacture
- Vaccine dried onto nanoprojections – no need for cold chain
- Vaccine delivered to dermis layer of skin with high concentration of immune cells – 150 times less vaccine required

#### The Journey

- 2006 Mark Kendall comes to UQ on a QLD Smart State Fellowship
- 2007-08 6 patents lodged, taken through PCT
- 2008-10 47 presentations to industry and investors
- 2009-11 Already receiving strong interest from pharmaceutical companies for use with their vaccines

#### **The Transaction**

- 2011, syndicate of 3 investors organised, due diligence managed, deal completed
- \$15m investment to take the technology through product development to first in-human studies and subsequent commercialisation







Commercialise intellectual property, expertise and research outcomes to create demonstrable value for UQ and ensure UniQuest is self-sustaining.







# Facilitate commercialisation to achieve profound commercial, environmental and social benefits.





#### **INPUT** UniQuest revenues (Average A\$ millions)

#### **OUTPUT** Cumulative funds raised (A\$ millions)

